Nasdaq · Biotech stocks database
CMND (Clearmind Medicine Inc. Common Shares) stock: $0.80, $1.7M market cap, $3.9M cash, -$2.2M EV, $0.1M fully diluted market cap. Next expected readout: Dec-26. Lead program: CMND-100 (Alcohol Use Disorder), Phase 1/2. Data from Fully Diluted's biotech stocks database.
| Cash | $3.9M |
|---|---|
| Debt | $0.0M |
| Net cash | $3.9M |
| Enterprise value | -$2.2M |
| Basic shares | 0.2M shares |
| Fully diluted shares | 0.2M shares |
| Fully diluted market cap | $0.1M |
| Cash per share | $24.50 |
Cash figures as of 2025-10-31. Database snapshot: 2026-09-21.
Loading CMND daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Feb 11 - Mar 25 | CMND-100 | Phase 1/2 | Alcohol Use Disorder | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.